Forgot Password?
Return to Course Listing

CME: Psoriasis: Best Practices, Barriers to Care, and Emerging Therapies in Medication Management

Activity Description / Statement of Need:

In this online CME self-learning program:


Psoriasis, characterized by chronic inflammation of the skin and hyperproliferation and abnormal differentiation of the stratified epidermis, is one of the most common autoimmune diseases in the U.S.  With a clinical presentation of red, scaly plaques on the skin that range in severity from minor, localized lesions to complete body coverage, it is also associated with inflammation of the joints and enthesial attachments and has potential of articular destruction – a complication known as psoriatic arthritis that affects up to 30-40% of those with the disease.


A recent trial suggested that the use of a follow-up visit shortly after initiating treatment may be an effective way to boost patients; use of their medication and achieve better treatment outcomes. Interventions such as selecting the right topical delivery vehicle, better drug design, formulation, or technology are some of the suggested areas of interest for the future.  A good physician-patient relationship, patient education, individualized treatment plan, psychological intervention, electronic devices, and returns visits are several other ideas suggested for better treatment outcomes particularly because the superficial nature of the disease lends itself to psychosocial comorbidity including: depression, anxiety, poor self-image and lack of self-confidence is prevalent within this population.  In particular, patients with moderate-to-severe psoriasis are vulnerable.  They report that their disease greatly impacts their daily lives in a negative manner, and studies have found these patients to have similar or lower quality of life when compared to people with chronic conditions including but not limited to cancer, arthritis, and cancer.


This program has been designed to bring healthcare professionals’ knowledge up to date with the currently best and recommended practices in treating Psoriasis.





Faculty introduction, disclosures

Introduction content: cursory refresher and review of Psoriasis

  • Epidemiology: statistics by severity
  • Clinical features, presentation, pathophysiology, disease progression, and comorbities
  • Patient case(s)

Treatment of Psoriasis

  • Clinical trial findings and guideline updates
  • Present pharmacotherapy: orals, topicals, and biologicals
  • Emerging and future therapies
  • Minimizing adverse effects
  • An increased focus on comorbidities
  • Other clinical pearls 
  • Optimizing patients’ adherence to their therapy 
  • Patient case(s)

Summary, conclusions, and best practice recap

Target Audience:

Healthcare professionals specializing in: dermatology, internal medicine, pediatrics, and those who otherwise commonly encounter patients with psoriasis.

This program is supported by an educational grant from Promius Pharma.

Release Date: May 16, 2016 -- Expiration Date: May 16, 2018

Faculty: Gary Cole, MD


Learning Objectives

By the end of the session the participant will be able to:

  • Describe the pathophysiology of psoriasis such that it might inform treatment mechanisms.
  • On the basis of clinical presentation, determine a patient�s psoriasis disease severity and describe their likely present and future comorbidities.
  • Identify the currently available and emerging pharmacotherapeutic treatments for management of psoriasis and apply them to patient cases using evidence-based medicine.
  • Evaluate a treatment plan for a specific patient with psoriasis to optimize safety and efficacy, suggesting modifications for improvement, including the management of comorbidities.
  • Describe the challenges and barriers to care associated with treating patients with psoriasis.



Faculty Disclosure and Resolution of COI

 As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.


Faculty Disclosure: Dr. Gary Cole, MD has no financial relationships to disclose.


Disclosures of Educational Planners: Charles Turck, PharmD has no relevent financial disclosures.


Commercial Support Disclosure: This program is supported by an educational grant from Promius Pharma.


  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowedge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Take the post-test
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural and Linguistic Competence

System Requirements

Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version

Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.

Additional Courses That Are Related To This Activity

Psoriatic Arthritis: Therapeutic Updates and Optimizing Treatment

Basal Cell Carcinoma (BCC): Therapeutic Updates, Best Practices, and the Role of Personalized Patient Care

Metastatic Melanoma: Updates from ASCO 2017